Blueshift Asset Management, LLC Fibrogen Inc Transaction History

Blueshift Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.94 - $12.96 $109,659 - $178,990	-13,811 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$12.02 - $16.79 $166,008 - $231,886	13,811 New	13,811 $166,000
Q4 2021 Feb 11, 2022	SELL	$9.93 - $15.39 $285,854 - $443,031	-28,787 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $293,051 - $766,885	28,787 New	28,787 $294,000
Q4 2020 Feb 12, 2021	SELL	$37.09 - $48.97 $223,096 - $294,554	-6,015 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $243,427 - $273,682	6,015 New	6,015 $247,000
Q1 2020 May 14, 2020	SELL	$23.3 - $45.96 $112,096 - $221,113	-4,811 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $166,364 - $231,216	4,811 New	4,811 $206,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.